News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stemline Therapeutics, Inc. (STML) Announces Five Presentations At The American Society of Hematology Annual Meeting, Including A Clinical Update Of SL-401 In BPDCN


11/14/2013 1:08:21 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced five presentations at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2013, at the Ernest N. Morial Convention Center in New Orleans, LA. Investigators will present a clinical update of SL-401, a novel targeted therapy directed to tumor bulk and cancer stem cells (CSCs), in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), as well as preclinical data of SL-401 in additional indications including multiple myeloma and chronic eosinophilic leukemia, a rare hematologic cancer. In addition, preclinical data of SL-101, a novel antibody-drug conjugate (ADC) directed to tumor bulk and CSCs, in FLT3-ITD acute myeloid leukemia (AML) will be delivered via oral presentation.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES